Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | TRPV3 | Q8NET8 | 7/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.31 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.31 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22345793 | 1.00 | ROCK2 (0.36) | ROCK2TRPV3KEAP1NFE2L2CYP1A2 | |
| SCHEMBL30850042 | 1.00 | ROCK2 (0.36) | ROCK2TRPV3KEAP1NFE2L2CYP1A2 | |
| SCHEMBL22345797 | 0.79 | TRPV3 (0.42) | ROCK2TRPV3CD274PDCD1PDCD1LG2 | |
| SCHEMBL20268380 | 0.79 | TRPV3 (0.42) | ROCK2TRPV3CD274PDCD1PDCD1LG2 | |
| SCHEMBL20268384 | 0.79 | TRPV3 (0.42) | ROCK2TRPV3CD274PDCD1PDCD1LG2 | |
| SCHEMBL30850026 | 0.79 | TRPV3 (0.42) | ROCK2TRPV3CD274PDCD1PDCD1LG2 | |
| SCHEMBL29442719 | 0.79 | TRPV3 (0.42) | ROCK2TRPV3CD274PDCD1PDCD1LG2 | |
| SCHEMBL20268528 | 0.69 | ROCK2 (0.41) | ROCK2TRPV3CD274ALDH1A1LMNA | |
| SCHEMBL20268529 | 0.69 | ROCK2 (0.41) | ROCK2TRPV3CD274ALDH1A1LMNA | |
| SCHEMBL9095902 | 0.68 | OPRK1 (0.39) | ROCK2CYP1A2CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313573-A1 | HYDROXYPYRIDOXAZEPINES AS NRF2 ACTIVATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-10-09 | — | — | US | disclosed |
| US-20240352034-A1 | HYDROXYPYRIDOXAZEPINES AS NRF2 ACTIVATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-10-24 | — | — | US | disclosed |
| CN-118206566-A | Hydroxypyridooxazepine as NRF2 activator | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-06-18 | — | — | CN | disclosed |
| US-11945826-B2 | Hydroxypyridoxazepines as NRF2 activators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-04-02 | — | — | US | disclosed |
| CN-113474349-B | Hydroxypyridooxazepine as NRF2 activator | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20220204526-A1 | HYDROXYPYRIDOXAZEPINES AS NRF2 ACTIVATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-06-30 | — | — | US | disclosed |
| EP-3924356-A1 | HYDROXYPYRIDOXAZEPINES AS NRF2 ACTIVATORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2021-12-22 | — | — | EP | disclosed |
| CN-113474349-A | Hydroxypyridooxazepine heptatrienes as NRF2 activators | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-10-01 | — | — | CN | disclosed |
| WO-2020165776-A1 | HYDROXYPYRIDOXAZEPINES AS NRF2 ACTIVATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204526-A1 | HYDROXYPYRIDOXAZEPINES AS NRF2 ACTIVATORS | KEAP1, NFE2L2, NQO1 | ROCK2 2547/4885TRPV3 335/4885KEAP1 1/4885 |
| US-11945826-B2 | Hydroxypyridoxazepines as NRF2 activators | KEAP1, NFE2L2, NQO1 | ROCK2 2547/4885TRPV3 335/4885KEAP1 1/4885 |
| US-20250313573-A1 | HYDROXYPYRIDOXAZEPINES AS NRF2 ACTIVATORS | KEAP1, NFE2L2, NQO1 | ROCK2 2547/4885TRPV3 335/4885KEAP1 1/4885 |
| US-20240352034-A1 | HYDROXYPYRIDOXAZEPINES AS NRF2 ACTIVATORS | KEAP1, NFE2L2, NQO1 | ROCK2 2547/4885TRPV3 335/4885KEAP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.